Thu, 04 Sep 2008 04:13:13 GMT
SEATTLE--(BUSINESS WIRE)--Techalt, Inc. (Pink Sheets: TCLT) ("Techalt" or "Company") announced the introduction of its Rim-Ice product at the Twelfth Annual 2008 BMW Homecoming for the BMW Z-3 and Z-4 roadsters in Greenville, SC. Consumers and dealers alike are buzzing about the product, its uniqueness in the market, and how much better it works compared to similar products. Distributors and dealers alike are providing positive feedback during the promo-giveaway. This annual pilgrimage is for the BMW car enthusiast and attracts thousands of people looking for the latest and greatest products to enhance the beauty of their automobile. Techalt believes Rim-Ice fits that bill.
Jay Lilley, the Parts Director for a high-end dealership in Tampa, Florida, has been going to the BMW Homecoming for 12 years, and is one of the “The Original Twelve, ” and has been carrying Rim-Ice for the past 2 years. Upon becoming Parts Director in Tampa, he integrated the product into their dealership inventory and received positive feedback. Similarly, the response at the BMW Homecoming has been incredible.
People are curious about ways to keep their wheels and chrome clean longer. At the BMW Homecoming event, over 11 cases of sample product, including marketing material, were handed out. Many representatives from the BMW Greenville Manufacturing plant offices were on hand at the BMW Homecoming Event, as well as representatives from Coachworks, Wheel and Rim magazines. All of these groups expressed interest in Rim-Ice and took samples, indicating there is a strong need in the market for Rim-Ice. Each one admitted there is a lack of a quick and easy-to-use, quality product that reduces brake dust and shines up chrome for the car enthusiast.
This market is untapped, per a senior representative of Coachworks, who believes there is an opportunity to generate approximately $20 million dollars of revenue per year by selling Rim-Ice through the Coachworks distribution system. Coachworks purchased a case of the product. Coachworks is looking to offer Rim-Ice through their catalog as the newest and fastest way to keep cars or motorcycles sparkling. Additionally, a president of a motorcycle chassis-building company indicated that there is a need for a quick chrome product that shines bikes fast -- Rim-Ice may be the solution to that problem.
Techalt believes the marketing research and visibility gained from introducing the Rim-Ice product at the BMW Homecoming was exceptional. Jeff Braswell of “South Atlanta BMW”, who has been stocking Rim-Ice in their parts department for 5 years, stated, “A product such as this, to reduce break dust, will make millions!”
Dave Moore, President and CEO of Techalt, commented, “I’m very excited with the reception we received at the Z-3/Z-4 Homecoming. This confirms that Rim-Ice is an excellent addition to our portfolio of products at Techalt.”
About Gorlen, Inc./Rim-Ice:
Rim-Ice is a consumer product designed and developed by Gorlen, Inc (“Gorlen”). Gorlen is a specialty chemical company which specializes in the innovative design and development of new consumer products for the automotive industry.
About Techalt:
Techalt, a holding company, dedicated to acquiring, licensing and financing start-up and mid-stage companies. Techalt focuses on innovative, alternative technologies, software, communications, environmental and health and wellness sectors.
Wed, 03 Sep 2008 22:15:35 GMT
SEATTLE--(BUSINESS WIRE)--Techalt, Inc. (PINK SHEETS: TCLT) ("Techalt" or "Company") announced today that it has commenced negotiations to acquire the product formula and the trademark ownership and rights for Gorlen, Inc.’s (“Gorlen”) product, Rim-Ice. The Company received a signed letter of intent from Gorlen outlining the proposed asset purchase agreement by the Company. Gorlen’s Rim-Ice brake dust repellent has been sold to automotive dealerships including BMW, Volvo, and Nissan as well as automotive parts and convenience stores, such as NAPA Auto Parts and Walgreens in the southern region of the United States.
Rim-Ice inventor/developer M. Gordon, the primary driving force behind the product, states, “We are excited about the possibilities and the potential for Techalt to facilitate the national promotion, distribution and sale of Rim-Ice. Our goal is nationwide exposure in high-end automotive dealerships, automotive detail stores, motorcycle sales and parts stores, drug and convenience stores. We have just completed the early-launch/market research stage. After a long search, we believe that uniting with Techalt Inc. is the right move at the right time!” Gorlen successfully launched the early launch/market research stage without the exposure from a formal marketing campaign and has since consistently received re-orders from the test markets for additional stock of the Rim-Ice product.
During its negotiations with Gorlen, Techalt intends to develop a national marketing campaign in order to reach the initial target market of the southeastern region of the United States, then launch a national sales and marketing campaign using a combination of radio, television, online and direct distribution methods.
About Gorlen, Inc./Rim-Ice:
Rim-Ice is a consumer product designed and developed by Gorlen, Inc (“Gorlen”). Gorlen is a specialty chemical company which specializes in the innovative design and development of new consumer products for the automotive industry.
About Techalt:
Techalt, a holding company, dedicated to acquiring, licensing and financing start-up and mid-stage companies. Techalt focuses on innovative, alternative technologies, software, communications, environmental and health and wellness sectors.
About Stan’s Rodeo Ointment (“SRO”):
SRO is a sports cream product designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain that often results from such injuries. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers, SRO is currently available by prescription and used by several prominent Olympic and professional athletes. Techalt also acquired the rights to develop Stan’s Blister Rub (“SBR”), which is a combination of materials that strengthen the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office with a patent expected in August 2008.
RECENT DEVELOPMENTS
Stan Johnson and Techalt representatives will make its first appearance as a standalone product at the 2008 National Athletic Trainers Association Annual Meeting in St. Louis, MO June 17 – 21, 2008. Stanley Johnston will be present at the conference to answer questions regarding specific uses and benefits of SRO. The conference is deemed the largest convention attended by athletic trainers, physicians, physical therapists and other medical personnel in the United States.
About the National Athletic Trainers' Association (NATA):
Athletic trainers are unique health care professionals who specialize in the prevention, diagnosis, treatment and rehabilitation of injuries and illnesses. The National Athletic Trainers' Association represents and supports 30, 000 members of the athletic training profession. NATA advocates for equal access to athletic trainers for patients and clients of all ages and supports H.R. 1846. Only 42 percent of high schools have access to athletic trainers. NATA members adhere to a code of ethics. www.nata.org.
SRO USES
BLISTERS
Blisters themselves can cause other more serious problems when an athlete adjusts his or her movements in reaction to the pain caused by the blister. For example, Mark Hubbard, president of American Specialty Underwriters, a leading baseball insurer, found that blisters sometimes cause pitchers to adjust their throwing mechanics just enough to expose them to more serious shoulder or elbow injuries. Due to the high cost of disabled pitchers (some costing $100 million a year in wasted salary), some teams will avoid such expense and pull the pitcher before the blister causes such problems.
While Neosporin® and other polysporin agents on the market provide antibiotic therapy for cuts and abrasion, there is virtually no other product on the market today other than SRO that has successfully targeted blister related injuries. Blisters are a common problem for other sports, including tennis, gymnastics, baseball, weightlifting, ballet, etc.
By applying SRO to blisters, pitchers are able to play without adjusting form or ball grip. Over twenty professional baseball teams use SRO and have expressed tremendous satisfaction with the product and suggested that it is the only product from which they have found an adequate remedy for the blisters. Ballet teachers and coaches have voiced similar concerns over blisters and have found similar successes with SRO. It is not uncommon for ballet dancers to continue their practice with broken toes and blisters commonly left open and raw. SRO protects the blister and toughens the skin while providing an antibiotic treatment to prevent infection.
ROAD RASH & ABRASIONS
Studies indicate that road rash and abrasions constitute another common use of SRO. On average, sports medicine physicians see at least eight to twenty patients per week who suffer from carpet burn, road rash and various abrasions.
By targeting road rash, SRO hopes to establish itself in a specific niche of the market, which like the blister market, has been neglected. The goal of road rash therapy is to seal and heal the injury. Commonly, a player will be prevented from playing because his wound reopens and begins to bleed. Athletic regulation prohibits any player from continued play where the wound continues to bleed. Current therapy options include local dressing and topical antibiotics, neither of which has proven successful. SRO, however, covers the entire injury and seals it, preventing any blood to escape while simultaneously acting to heal the wound.
SIDE EFFECTS
Toxicological studies have found no significant adverse side effects. Consumers using SRO have indicated minimal local discomfort when administered, while some say they have used SRO ritualistically without any problems whatsoever. Other potential side effects may include a stain on clothing.
COMPETITION
According to some within the industry, the size of the wound care market is approximately $150 million per year. Mr. Johnston believes there is no other existing compound or product, either synthetic or naturally occurring, which has reported similar biochemical actions and properties, i.e., successfully sealing the wound while preventing oozing of blood and decreasing healing time. Current therapies include wound dressing and antibiotic treatment, neither of which offers superior remedy. Existing products on the market used to treat these types of injuries include Neosporin® and Bacitracin®.
STAN'S BLISTER RUB
Mr. Johnston has developed a product to compliment SRO, commonly known as “Stan’s Blister Rub” (“SBR”), a wet sand-like texture which is designed to be applied after usage of SRO in order to toughen the skin following the healing of blisters to prevent further blisters and irritations.
PRODUCTION
SRO and SBR are currently being compounded by Living Well Pharmacy Inc., d/b/a HNP Pharmaceuticals (“Living Well”), a pharmaceutical compounding laboratory that compounds medications by prescription. Living Well has a non-exclusive license to directly compound SRO and SBR on a prescription basis. Living Well currently receives 33% of the aggregate gross sales of all SRO and SBR compounded by Living Well during each calendar quarter.
MARKETING AND SALES
SRO is currently available in a prescription formula, with the intent on obtaining over the counter (“OTC”) certification within the next 24-36 months. Current revenue is $60, 000 per year, with current marketing activities consisting solely of “word of mouth”. With a definitive sales and marketing plan currently being developed by Techalt, it is believed new exposure will lead to an increase in SRO’s sales due to an expanded customer base.
Techalt is currently in the process of identifying local test markets to conduct focus groups regarding and perform demonstrations of SRO to expand its marketing and brand awareness.
About Techalt:
BACKGROUND
Stan’s Rodeo Ointment (“SRO”) is a new chemical agent for sport-related injuries that significantly shortens the healing time for abrasions, lacerations and blisters, while diminishing the pain that is often related to such injuries. Developed by a former professional rodeo rider and major league baseball head trainer, SRO is used by athletes competing on the high school, collegiate, Olympic and professional levels, as well as those individuals commonly known as the “weekend warriors.” This new remedy, currently available on a prescription basis, allows athletes of all ages to “play on through” some of the more common injuries without jeopardizing their athletic capacities.
Originally developed in 1980, SRO accelerates the healing time associated with blisters, abrasions, incisions, lacerations and open wounds to the skin by applying a combination of the following active ingredients: Bacitracin, Polymyxin, Tincture of Benzoin, Povidone Iodine, Phenylephrine, 8-hydroxyquinoline, Ichthammol and Hydrocortisone. Feedback from athletes suggest SRO reduces the healing time of dermal wounds by anywhere from one-third to one-half the normal time.
SRO was developed by Stanley Johnston (“Mr. Johnston”), a former professional rodeo rider who also served as Head Trainer for the Los Angeles Dodgers and spent 23 years with the organization. While competing on the professional rodeo tour, Mr. Johnston endured countless injuries, none more prevalent than the hand blisters he suffered which would tear the skin from his riding hand. Finding no successful remedy on the market, Mr. Johnston decided to create his own remedy and developed what athletes throughout the country now know as “Stan’s Rodeo Ointment.” Mr. Johnston has sold batches of SRO to twenty Major League Baseball clubs and it is estimated that at least two dozen professional pitchers use SRO on a regular basis.
While SRO has found perhaps its greatest success among the professional baseball leagues, Mr. Johnston, through his licensing of SRO to Techalt, Inc., a Nevada corporation (“Techalt” or the “Company”), now seeks to expand SRO’s usage among professional athletes and those athletes competing on all competition levels, in addition to the continually expanding “weekend athletes” market.
Various newspapers and sports, health and business periodicals around the Country have reported on SRO’s success, which has led to an increase in sales. With this media foundation already laid, Techalt intends to expand SRO’s marketing, which will include testimonials and endorsements from several Olympic and professional athletes and medical professionals.
An application for patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office.
INVENTOR BACKGROUND
Stanley Johnston. Mr. Johnston is the inventor of SRO and SBR. Mr. Johnston is currently a retired Certified Athletic Trainer, most recently with the Los Angeles Dodgers, where he served as an athletic trainer for 23 years, including several years as Head Athletic Trainer. Prior to working with the Dodgers, Mr. Johnston was a professional rodeo competitor for 10 years. Mr. Johnston has been an innovator of many products and techniques utilized in the Sports Medicine field. Having worked on the high school, collegiate and professional levels, Mr. Johnston knows what it takes to make an athlete reach his or her full potential. Mr. Johnston earned a degree in physical education with an emphasis in sports medicine at Western Montana College and a master’s degree from Montana State University.
Wed, 06 Aug 2008 12:44:34 GMT
SEATTLE--(BUSINESS WIRE)--Techalt, Inc. (PINK SHEETS: TCLT - News) ("Techalt" or "Company") announced Stan’s Rodeo Ointment (“SRO”) will be dispensed at the 2008 Beijing Olympic Games. SportPharm (the compounder of SRO, FDA licensed distributor and Subsidiary Compounding arm of HNP Pharmaceuticals) will be participating in its second Olympic Games as a member of the U.S. Olympic Medical Team. SportPharm will feature SRO at the Olympic Games and packages all of the medications it dispenses for use by the U.S. Olympic Team (athletes and staff).
Multiple NFL, NBA, MLB, NCAA, MLS and NHL teams utilize SportPharm’s dispensing databases to provide their organization with a majority of their pharmaceutical needs. As the Chief Pharmacist of SportPharm, Mike Pavlovich will be responsible for the management of all the dispensing databases and will serve as the only Pharmacist of the 45 member medical team. Additionally, he will provide medications and drug information services to athletes and staff alike, where he will be using SRO as an Olympic-Approved ointment to heal mild to severe dermal wounds.
“We feel the Beijing Olympics are an ideal platform to showcase the benefits athletes can realize when using SRO. We expect the visibility derived from dispensing SRO at the Beijing Olympics will help our sales and distribution efforts in the United States, ” stated Techalt’s CEO David Moore.
Techalt is currently in the process of securing financing for (i) expanding SRO’s distribution channels and marketing efforts and (ii) completing the process for obtaining an over the counter designation from the United States Food and Drug Administration.
About HNP Pharmaceuticals (“HNP”):
HNP Pharmaceuticals is a nationally recognized pharmaceutical compounding laboratory, specializing in unique and patent-pending compounded formulations for orthopedic injuries. HNP is the primary compounding pharmacy for more than 70% of all professional athletes in the United States, the Olympics, and an ever-growing number of collegiate sports programs.
About Stan’s Rodeo Ointment (“SRO”):
SRO is a sports cream product designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain that often results from such injuries. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers, SRO is currently available by prescription and used by several prominent Olympic and professional athletes. Techalt also acquired the rights to develop Stan’s Blister Rub (“SBR”), which is a combination of materials that strengthen the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office with a patent expected in August 2008.
Tue, 05 Aug 2008 18:39:51 GMT
SEATTLE--(BUSINESS WIRE)--Techalt, Inc. (Pink Sheets: TCLT - News) (”Techalt” or the “Company”) announced today that Navy personal aboard the USS Ronald Reagan are using its’ product, Stan’s Rodeo Ointment (“SRO”), as a healing ointment to repair abrasions incurred in connection with the fulfillment of their duties. David Moore, CEO of Techalt stated, “For the past eighteen months, the US Naval Medical staff of the USS Ronald Reagan has been using Stan’s Rodeo Ointment to treat Naval Personnel. The military’s utilization of our licensed product further demonstrates its effectiveness and, ultimately, its broad OTC applications.” The USS Ronald Reagan deployed in May 2008 for a six-month tour to support the efforts in the war in Iraq.
The USS Reagan's Chief Surgeon, Dr. George Linville, began using SRO in January 2007 on cuts, scrapes, blisters, and skid burns that sailors and aircrew received from their demanding duties. Prior to the Gulf deployment, Dr. Linville stated, “SRO has the highest efficacy of any topical ointment I have ever used. In my 30 years of treating wounds I have never had an ointment that heals wounds like this.” SRO is currently undergoing acceptance into the medical supply list for all branches of the US military.
Techalt is currently in the process of identifying financing for expanding the distribution of SRO to other customers. Furthermore, Techalt is seeking to secure (i) additional contracts and (ii) over-the-counter approval from the United States Food and Drug Administration. Once SRO has received approval to be distributed as an over-the-counter product, SRO will compete in the same product sector as Neosporin, which realized approximately $22, 000, 000 in gross revenue in its first year of over-the-counter distribution.
About Stan’s Rodeo Ointment (“SRO”):
SRO is a sports cream product designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain that often results from such injuries. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers, SRO is currently available by prescription and used by several prominent Olympic and professional athletes. Techalt also acquired the rights to develop Stan’s Blister Rub (“SBR”), which is a combination of materials that strengthen the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office with a patent expected in August 2008.
Thu, 12 Jun 2008 18:55:53 GMT
MANALAPAN, NJ--(MARKET WIRE)--Jun 12, 2008 -- Dynamic Media Holdings, Inc. (Other OTC:DYMH.PK - News), a company that developed an innovative hair and sunscreen product for balding men, announced today that it will market a version of SUN & STYLE, its new sunscreen hair spray product, for active women.
Very often, active women who are exposed to the sun will burn their part lines and exposed areas such as on the crown of their heads. Having a broad spray sunscreen or thick lotion is not a desirable option for sunburn protection. SUN & STYLE has developed the perfect solution for women. To be sold in small travel packs, we will offer the SUN & STYLE sunscreen in formula-fill cotton swabs. Gently snap the tip of the swab and the formula will flow to the other tip. Women can then apply the sunscreen to very targeted areas, such as their part lines. Easy to use and convenient to carry, SUN & STYLE for women is a unique product that we are very confident will have great consumer demand.
ABOUT SUN & STYLE
SUN & STYLE hair and scalp spray is an exciting new hairstyle and sunscreen product that will be uniquely marketed to men who have male pattern baldness, thin or thinning hair. SUN & STYLE is the only sunblock hair and scalp product to be marketed directly to men with thinning hair. Our unique product, with SPF 15 sunblock and UVA and UVB broad spectrum sun protection, when applied, will allow you to style your hair and leave it completely natural looking and manageable and still protect your scalp from the sun's harmful rays. Other sunscreen products, when sprayed on the hair, will make hair oily, gooey, unmanageable or rock hard. We are confident that this marketing and advertising strategy will make SUN & STYLE stand out, fill a huge market void and create a unique and successful new product that will appeal to millions of men.
Male pattern hair loss is the most common form of hair loss, representing close to 94% of all hair loss in men. And about half of all men experience this common hair loss by age 50. If you are a man between the ages of about 20 to 50 and you start to lose hair, then the chances are 95 percent certain that you are experiencing male pattern baldness. As the term suggests, male pattern baldness follows a typical sequence or pattern. Hair loss can start in different areas, but is usually at the temples and/or on the crown of the head. Initial thinning of hair progresses over a number of years and may lead to total baldness but more typically loss of hair over the top surface of the head. By age 35, two-thirds of American men will have some degree of appreciable hair loss and by age 50 approximately 84% of men have significantly thinning hair. About 26% of men who suffer from male pattern baldness begin the painful process before they reach the age of 21.
About Dynamic Media Holdings, Inc.
Dynamic Media Holdings, Inc. will continue to aggressively expand as it plans to introduce several new products to the marketplace. In addition to its publishing, graphics, advertising and web development divisions, the company is executing a strategy of using its core magazine products to springboard and launch a diverse array of ancillary products thereby maximizing its product branding and potential. "It is a very exciting time and opportunity, " CEO Bruce Schoengood states. "We plan to initiate a comprehensive strategy to the marketplace launching cutting-edge websites with a strong online presence as well as penetrating the traditional brick and mortar sectors and avenues. Visit www.dymholdings.com for more information."
Thu, 29 May 2008 13:18:03 GMT
SCOTTSDALE, AZ--(MARKET WIRE)--May 29, 2008 -- Bancroft Uranium Inc. (OTC BB:BCFT.OB - News) ("Bancroft" or the "Company") today is pleased to announce the first drilling results from the Spring 2008 surface drill program being conducted at the Monmouth Uranium Project, near Bancroft, Ontario. Noteworthy assay results from the first 13 holes are outlined below.
The 2008 Exploration Phase 1 drill program commenced on February 25th and was designed to focus on areas in and around the historical drill results from the 1969 program bringing it into modern N.I. Policy 43-101 compliance, a recognized world mining standard. The drilling is also designed to extend the known strike length of the skarn which hosts the uranium mineralization with the aim of expanding the current estimated 1, 800, 000 lbs U3O8 potential at Monmouth.
Initial drill assays and intervals are from holes drilled from the most southwesterly exposure of the host rock skarn (altered limestone) and are spaced approximately 100 feet apart. Significant results are as follows. Assays are noted as lb representing lbs/ton U3O8 over feet:
08-1 0.803 lb/12.5' from 55.3 to 67.8 feet in skarn, 0.344 lb/30.5'from 182.1 to 212.6 feet in pegmatite and 0.805 lb/13.8' from 276.2 to 290.0 feet in skarn including 1.02 lb/9.3' from 280.7-290.0 feet. Visible uraninite was noted
08-5 0.139 lb/34.8' from 235.6 to 270.4 feet in pegmatite
08-6 0.466 lb/10.0' from 16.0 to 26.0 feet in pegmatite
08-7 0.291 lb/7.9' from 44.0 to 51.9 feet in skarn with visible uraninite
08-8 0.540 lb/60.6' from 15.0 to 75.6 feet in skarn
08-9 0.596 lb/51.9' from 31.0 to 82.9 feet including 0.315 lb/14.9' from 31.0 to 45.9 feet and 0.923 lb/24.5' from 51.0 to 82.9 feet with visible uraninite, molybdenum
08-10 0.740 lb/52.2' from 12.8 to 65.0 feet including: 0.915 lb/32.0' from 12.8 to 44.8 feet and 0.616 lb/15.0' from 50.0 to 65.0 feet in skarn with visible uraninite
08-12 0.513 lb/49.9' from 6.3 to 56.2 feet in skarn with visible uraninite noted
08-13A 0.332 lb/25.1'from 9.3 to 34.4 feet with visible uraninite noted
The above holes represent testing across the initial 300 feet of historical strike length which totals 1, 500 feet. Early results have verified the location, thickness and flat lying geometry of the uranium bearing skarn system intersected in the historical drilling. U3O8 assays have been returned from both uraninite bearing bright orange-colored calcite alteration in the skarn and from several pegmatite bodies in and adjacent to the skarn package. Initial assay results from the skarn rocks appear to validate the historical data. As drill holes progress through the central portion of the deposit, the historical intersected thicknesses of the uranium bearing skarn appear to increase as do grades based on limited assay data. Initial assays returned from the pegmatitic rocks are better than expected based on the historical work.
The geological modeling of the deposit is now coming into focus with the alteration zone rock package dipping at a fairly consistent 25-30 degrees, amenable to a potential open pit scenario.
All of Bancroft Uranium's exploration programs are designed and supervised by Qualified Persons ("QP") under the N.I. Policy 43-101, who ensure that programs are carried out using current industry "Best Practices." The spring 2008 drilling program was supervised by Murray McGill P.Geo (QP). The NQ size core was logged by Mr. McGill and split on-site. Half core samples were analyzed using standard Delayed Neutron Counting (DNC) methods by Activation Laboratories in Ancaster, Ontario. Activation Laboratories employs rigorous in-house QA/QC procedures in the DNC process.
Bancroft will release a second series of drill results shortly.
For inquiries from the public and media concerning the Monmouth Uranium Project please contact Greenspirit Strategies at 1-877-54 GREEN or 1-877-544-7336. For shareholder and investor information please contact investor relations at 1-866-860-2995
ABOUT BANCROFT URANIUM INC. (OTC BB:BCFT.OB - News)
Bancroft Uranium Inc. is an exploration Company which intends to develop Uranium assets in North America. Bancroft's initial asset, the Monmouth Uranium Project is envisioned to have the potential of a low cost, open pit uranium producer located close to infrastructure and end product buyers.
Recent unprecedented rises in the price of Uranium have been over $90 per pound recently with extraordinary fluctuations exceeding $135/lb. These prices reflect a 1000% increase over the past 7 years - with most of these gains occurring within the past 2 years.
In response, Bancroft Uranium has moved to quickly develop a portfolio of Uranium projects that includes the Monmouth Uranium Deposit - an extremely significant project due to the historical work previously performed but not fully developed due to low prices during the original work.
The Company has also begun early stage efforts in the Long Lac area as well as the prolific Elliot Lake Uranium camp.
Tue, 27 May 2008 16:12:12 GMT
Scottsdale AZ, May 27, 2008 -- (Market Wire) -- Bancroft Uranium Inc. (OTCBB: BCFT) (“Bancroft” or the “Company”) today wishes to announce that Francis Gaskins of IPODesktop.com has issued an independent third party analyst report on the Company. Based on the report's growth assumptions, Francis Gaskins believes the market capitalization could approach $90 to 92 million, or $2.00 per share. The public is free to review this report at http://www.gaskinsco.com/linkto-bcft.shtml
About Francis Gaskins:
“Francis Gaskins, a seasoned financial analyst, is noted as the Internet's most experienced, analytical web cast producer and interviewer. Often quoted, his scope of influence includes editor (IPOdesktop), Talk Radio, Internet TV, and Video Productions, plus numerous articles and opinions published in the nation's financial media.
As the IPO Desktop editor, Gaskins is one of the leading provider of independent IPO research for professional money managers and individual investors. One of “Forbes Best IPO Sites”, he is widely quoted by the IPO media including the Wall Street Journal, Dow Jones Business News, Dow Jones Newswires, Reuters, USA Today, TheStreet.com, CBS MarketWatch. IPOdesktop editors are quoted by The Wall Street Journal, Dow Jones Newswires, MarketWatch, Reuters, USATODAY, and others.
IPO Hardball!, the weekly podcast, is hosted by Gaskins at Streetiq.com. Gaskins himself often appears as a guest IPO commentator for CNBC and Bloomberg Television. On the internet, Gaskins is Co-host for the weekly IPO Hardball! Internet radio show, also broadcast from CBS Marketwatch. Mr. Gaskins holds a Harvard University Master of Business Administration (Finance) and from Princton, a degree in Economics. He has extensive experience in sales, marketing, pre-IPO financial analysis and valuations, fund raising, forecasting and budgeting, strategic modeling, general ledger and preparation of financial statements and market research.”
ABOUT BANCROFT URANIUM INC. (OTC BB:BCFT.OB - News)
Bancroft Uranium Inc. is an exploration Company which intends to develop Uranium assets in North America. Bancroft's initial asset, the Monmouth Uranium Project is envisioned to have the potential of a low cost, open pit uranium producer located close to infrastructure and end product buyers.
Recent unprecedented rises in the price of Uranium have been over $90 per pound recently with extraordinary fluctuations exceeding $135/lb. These prices reflect a 1000% increase over the past 7 years - with most of these gains occurring within the past 2 years.
In response, Bancroft Uranium has moved to quickly develop a portfolio of Uranium projects that includes the Monmouth Uranium Deposit - an extremely significant project due to the historical work previously performed but not fully developed due to low prices during the original work.
The Company has also begun early stage efforts in the Long Lac area as well as the prolific Elliot Lake Uranium camp.
Mon, 19 May 2008 13:26:44 GMT
VShield Software Corp. Is Adding Its Anti Virus and Anti Spam Tools to VSArmour Software
DOVER, DE--(MARKET WIRE)--May 19, 2008 -- VShield Software Corp. (Other OTC:VSHE.PK - News) today announced that it will be adding a new suite of tools specifically targeting malicious software in the form of viruses, spam, spyware, worms and Trojan Horses. The new tools will be tightly integrated into the VSArmour kernel and will act in conjunction with its other security systems and features. Although the present data treatment and access security does not allow for the retransmission of valuable data files, VShield Software felt that the introduction of world class extensions to its software would further deter any attacks and allow the network managers to strengthen and tune their security further. VShield Software will be announcing which heuristic recognitions systems it will be incorporating for the recognition of its antivirus and anti spam toolsets and once completed they will be from a world recognized vendor and best in class. The combined software suites will be the safest product on the market today and will allow the network security specialist the tools they have been waiting for.
"This integration of the new malicious software recognition and neutralization technology will allow our clients worldwide to have the most secure working environments possible. No virus, worm, hacker, inside or outside spy, disgruntled employee, Trojan horse, scam or lost hard disk will ever allow sensitive data to fall into the wrong hands. We intend to tame the wild online Internet, stop inside and outside data theft and ensure that no credit card information is stolen from any of our clients ever again. IT professionals can now sleep again as we will put back the private in private networks and slam the door shut on hackers and thieves, " stated Patrick Burke.
About VShield Software Corp.
The company designs, produces, markets and sells leading edge computer security software programs that feature advanced software development and technologies that are superior to other products on the market. All of the Company's security systems are based on previously proven and field tested large commercial security systems. These systems are based on hiding, disguising and encrypting various levels of files maintained on a computer such that an intruder is unable to obtain information from a desired file. This is unlike existing 'firewall' systems now on the market which are focused on keeping intruders from gaining unauthorized entry to a computer. Where applicable, products are patent and copyright protected in both Canada and the United States.
Tue, 13 May 2008 14:03:00 GMT
HEATHROW, Fla., May 13 /PRNewswire-FirstCall/ -- Quality Restaurant Ventures Inc. (OTC Pink Sheets: QRVS - News) today released further information concerning its business and operational plans for its new quick serve food brand, Caffe Porta Via. The preliminary business plan calls for QRVS to initially license the concept to qualified individuals directly through the company, then eventually through a network of area developers located in major metropolitan areas in Florida and the southeast U.S.
"We've made Caffe Porta Via very easy to own and operate, " explained QRVS President Tim Murray. "Quality will provide brand licensing rights, an initial marketing package, food purchasing contacts and complete training for our licensees in exchange for the purchase of a license and a monthly licensing fee. We believe Caffe Porta Via will appeal to individuals who see this as an opportunity to get in business of their own that provides a reasonable income without major operational and financial burdens."
Caffe Porta Via is a stand alone kiosk, custom designed to complement the office lobbies they occupy. The units are fully equipped and will serve breakfast items, sandwiches and salads, and snack foods, along with premium and specialty coffees. The marketing program will include menus, signage and email programs for employees near the location. No decision has been reached concerning the cost of an individual unit license or the formula that will be used for an area developer agreement.
About Quality Restaurant Ventures Inc.
Quality Restaurant Ventures Inc. develops new restaurant concepts, and invests in regional fast-food concepts with high growth potential, enhancing their operations while preparing them to become national franchise opportunities.
Mon, 12 May 2008 21:55:57 GMT
HEATHROW, Fla., May 5 /PRNewswire-FirstCall/ -- Quality Restaurant Ventures Inc. (OTC Pink Sheets: QRVS - News) today announced the name of its new quick serve food brand. Caffe Porta Via is QRVS's latest food concept designed to operate as free-standing kiosks in large commercial complexes and office buildings. A contract from an undisclosed commercial real estate company in Central Florida has been signed and two units are being currently constructed for installation and opening this summer.
"I believe Caffe Porta Via is going to be a winner because it addresses a huge problem in many office complexes in cities across the country, " projected QRVS President Tim Murray. "Employees today are being squeezed for both time and money. With the price of gasoline, the time it takes to drive to work, go to an off-premise often crowded lunch spot, and then get back to work in an hour or less, it's no wonder that there is a growing demand for the breakfast and lunch solutions that Quality offers."
Caffe Porta Via is a stand alone kiosk, custom designed to complement the office lobbies they occupy. The units are fully equipped and will serve breakfast items, sandwiches and salads, and snack foods, along with premium and specialty coffees.
QRVS has recently developed a new marketing piece that ties all three brands, Sobik's Sub Shops, Wing Way and Caffe Porta Via together as food service solutions for industrial and commercial complexes and office buildings.
About Quality Restaurant Ventures Inc.
Quality Restaurant Ventures Inc. develops new restaurant concepts, and invests in regional fast-food concepts with high growth potential, enhancing their operations while preparing them to become national franchise opportunities.
Mon, 05 May 2008 20:34:42 GMT
Founder, Chairman, President & CEO Edward C. Feintech Discusses Stock's Recent Price Drop and Announces Focused Marketing and Operating Plans That Capitalize Upon Restaurant Industry's New Troubles From Economic Issues
APTOS, CA--(MARKET WIRE)--May 5, 2008 -- Smoky Market Foods, Inc. (OTC BB:SMKY.OB - News); A Letter From Edward C. Feintech, Chairman and CEO:
As the largest single shareholder in SMKY (through my cash-invested ownership in Smoky Systems), I have been deeply and directly affected by the recent, steady drop in SMKY's stock price these past weeks amidst a large amount of selling. I am sure that for other SMKY shareholders, seeing the value of your equity position in SMKY drop so dramatically has been of deep concern as well. The purpose of this letter is to provide an explanation as to what I believe is happening with our stock and to announce a change in our marketing and operating strategy, which I believe creates a positive opportunity for SMKY and its potential business partners out of the recent decline in the performance of the restaurant industry.
Relative to SMKY stock, I believe that the price of our stock has declined during the past weeks, and especially this past week, primarily because of our efforts to secure financing to pursue our business plan. Our need to raise capital has been referenced in our recent filings and is well known in the investment community. It is normal for the market price of a company's common stock to decline when it is seeking capital, in part because of anticipated dilution. In addition, with an early stage company seeking a substantial amount of capital, it is common for prospective investors, or those otherwise aware of possible transactions, to begin taking steps -- primarily short selling -- in order to push down the price of the company's common stock. Since any financing will be based upon the market price of the company's common stock, if a prospective institutional investor or group of investors can take steps to put downward pressure on the stock price, this will reduce the price they will pay in any financing or create other opportunities for profit if the stock price bounces back.
With a company, such as SMKY, that is pre-revenue and has low trading volume, an institution or group working together can severely harm the company's stock price by continuing to sell tens of thousands of shares, even if they don't own the stock they are selling. Such efforts dramatically affect the price of a company's stock, without any reference to the future potential of the company. I am optimistic that this recent downturn in our stock price will be temporary and that the future of our company, and our stock price, remains bright.
Relative to our marketing and operating plan, I am announcing a revised marketing and operating strategy focused less on building a number of independent restaurant-stores in the short term and more on installing stations and kiosks in existing locations in order to create immediate-term revenue for us and our business partners.
In just the time since SMKY became public, due to severe economic turns with rising fuel costs, rising food costs, lower consumer spending, and rising employee costs for wages and workman's comp, the restaurant industry has entered a well-publicized downturn. Indeed, most regional and national chains are reporting drops in customer counts, revenue, and profits and for the near and longer term forecast, the trend is not expected to end. This turn of events creates a problem for our plan to open a large number of restaurants in the near term.
However, I believe the restaurant industry's dilemma represents an opportunity for SMKY in that it makes our foodservice menu system concepts and our 35s/f and 70s/f stations, and 150s/f self-contained kiosks, potentially attractive to existing restaurants and other venues in need of more income. We are seeking to enter into agreements to install the foodservice stations and kiosks inside chain venues (restaurants, delis, juice stores, convenience stores, retail venues, etc.) and operate them as lease departments, by which we pay the host venue a fixed amount of space rent against a percentage of sales in exchange for the space in which to set up our station or kiosk. This represents an opportunity for the host venue to obtain incremental revenue without additional cost. SMKY will benefit by being able to get its products and brand in front of customers on a large scale basis, without significant per-venue up front costs.
As we are able to obtain financing, our marketing and operating plan is to position SMKY to grow revenue aggressively, but with much less debt and fixed operating expense exposure. We will intensify our focus on generating revenue through a multi-channel distribution which includes stations and kiosks, and our packaged retail and Internet operations. We will continue to open some Smoky Market restaurant-stores, but in reduced numbers and in strategic locations throughout the country for the purpose of menu product testing and system training for Franship(TM) operators of the stations and kiosks. Our retail merchandising and Internet operations for sales of packaged foods continues to be a significant distribution channel for us to develop, as consumers travel less to restaurants and purchase more quality prepared foods for in-home consumption.
About Smoky Market Foods™
Smoky Market Foods™—It’s been a long time com’n, but well worth the wait!
The unique quality of Smoky Market® brand foods has been developed over the course of Eddie Feintech’s long career in smoked food cook‚n, which began back in 1977 with the opening of his first “Rib Joint” barbecue restaurant in Des Moines, Iowa. Eddie’s wood-burning ovens would authentically and very uniquely Smoke-Bake™ meat and fish using freshly cut hickory timber to impart natural and penetrating smoky flavor. The small brick and iron ovens would yield about 700 pounds of tantalizing smoky meats every 12 hours in fresh preparation for each day’s business...
Many years of costly development were required to get the smoking technology of his restaurant “smokers” approved by the USDA for commercial mass production of meat and fish. The little brick and iron smoker design has now evolved into a huge stainless steel, wood-burning oven system capable of producing over 15, 000 pounds per day of precisely the same quality of smoked foods that had made his restaurant enterprise so successful.
Our unique line of delectable Smoke-Baked™ cuisine is produced in a large USDA-inspected processing facility located in Webster City, Iowa, the heart of the Mid-West! Watch for the openings of Smoky Market restaurant-stores, kiosks, and our new web site for Internet ordering.
Fri, 02 May 2008 15:42:49 GMT
HEATHROW, Fla. April 28 /PRNewswire-FirstCall/ -- Quality Restaurant Ventures Inc. (OTC Pink Sheets: QRVS - News) announced today that it has initiated a broad based marketing program to support the company's Wing Way and Sobik's quick serve food brands. Additionally the Central Florida based company is set to unveil a new food brand targeting commercial and industrial centers. Since Mr. Tim Murray was appointed President of QRVS at the beginning of 2008 numerous operational, personnel and marketing changes have taken place.
"Our current push is to realign Quality's flagship brand Sobik's with its 39 year history in Central Florida, " explained Murray. "Sobik's heritage runs deep in this community where we've been recognized as the hometown sub shop chain that has always served the biggest and best steak subs in town. We decided to turn this long-standing reputation into our market positioning and take advantage of the many creative avenues this opens for promotions, merchandising and advertising."
Sobik's opened its first Orlando location in 1969 and currently has 22 franchised sub shops in the Central Florida marketplace. Three Sobik's franchises also operate with Quality's co-brand Wing Way, which serves several types of buffalo wings, as well as Angus burgers and fries. The young brand's positioning capitalizes on promoting its image with a combination of street signs and road icons such as red stop signs and yellow road signs all leading down roads to Wing Way locations.
QRVS also expects to soon unveil the name of its new division targeted at food service operations in large office buildings. The company is just completing operational and menu refinement at an undisclosed test location.
Quality believes that this is a largely untapped marketplace where food service locations are needed to serve office workers pressed for time at breakfast and lunch. Quality has recently developed a new corporate collateral piece targeted at area developers and real estate management companies that ties all three brands together as food service solutions for large industrial and commercial complexes.
About Quality Restaurant Ventures Inc.
Quality Restaurant Ventures Inc. develops new restaurant concepts, and invests in regional fast-food concepts with high growth potential, enhancing their operations while preparing them to become national franchise opportunities.
Thu, 24 Apr 2008 15:25:48 GMT
Company Will Offer Licenses in Selected Markets to Qualified Professionals
CARSON CITY, Nev.--(BUSINESS WIRE)--VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI - News), a Nevada corporation, today announced it will offer licenses in select markets for Diabetes Treatment Centers.
The license will allow qualified professionals to administer the highly successful iCAT Therapy to patients with Type 1 and Type 2 diabetes. VitalCare will offer complete setup and training to all personnel at each center with a comprehensive ongoing support program. Licenses will also be offered to qualified medical groups and HMOs.
Jimmy McDougald, CEO of VitalCare, stated, “This is a unique opportunity for all those in the medical field who really want to make a difference in the lives of patients with Type 1 and Type 2 diabetes. The results of iCAT Therapy are well documented and speak for themselves.”
Wed, 23 Apr 2008 00:59:44 GMT
National Launch of FDA Approved iCAT Therapy Begins
VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets: VDTI), a Nevada Corporation, today announced the national launch for opening licensed diabetes treatment centers utilizing the micro-dose intravenous insulin pump technology together with proprietary algorithms and clinical protocols for providing Intercellular Activation Therapy (iCAT) for treating diabetes.
The iCAT treatment is currently being administered at several clinics in Arizona, Nevada, Utah, Florida, Texas and Puerto Rico, to those who suffer from Type 1 and Type 2 Diabetes, in addition to secondary complications of Type 2 Diabetes including hypertension, peripheral vascular disease, retinopathy, heart disease, peripheral neuropathy, kidney disease, and diabetic wounds.
Jimmy McDougald, CEO, stated, “Due to VitalCare’s clinical specialists’ succeeding in the treatment of Type 1, Type 2 and Secondary Complications of Type 2 Diabetes over the past two decades, our executive board has decided to open opportunities for licensing VitalCare Diabetes Treatment Centers affiliates with certified training for qualified healthcare providers, for the licensing and use of iCAT Therapy. It is VitalCare’s goal to make iCAT Therapy more accessible to the 21 million diabetics in North America. The VitalCare Diabetes Treatment Centers will either be company owned, joint ventured or licensed to select qualified medical professionals.”
Tue, 22 Apr 2008 15:46:10 GMT
National Announcement of FDA Approved Infusion Technology
CARSON CITY, Nev.--(BUSINESS WIRE)--VitalCare Diabetes Treatment Centers, Inc. (NASDAQ: VDTI - News), a Nevada Corporation, today announced the FDA approval (called allowance to market) exists for the infusion devices used by VitalCare for its Intracellular Activation Therapy (iCAT) treatment of Type 1 and Type 2 diabetes. Jimmy McDougald, CEO stated, stated, “This is a major factor in the establishment of our treatment centers, as we begin to move iCAT into the commercial market.”
iCAT Therapy utilizes the special use micro-pulse insulin delivery pump with proprietary software (algorithms) incorporated into its logic. This uniquely designed pump delivers small “micro-doses” of insulin in a pattern which mimics the way a normal pancreas secretes insulin which is used by the liver. iCAT Therapy also uses “real-time” measurements of the patient’s blood sugar levels and bodywide metabolic rate by the use of a metabolic measurement cart. This data is inputted into the pump which automatically adjusts the next insulin dosage to stimulate more normal metabolism. The metabolic cart uses state-of-the-art technology to measure exhaled CO2 from the exhaled breath of the patient, and the result of our iCAT Therapy is the “reactivation” of normal metabolism in the patient. With normalization of liver enzyme functions, the body’s cells begin to utilize glucose, something that people with diabetes cannot do normally. This treatment restores the optimum metabolism bodywide which promotes healing.
By addressing the core problem of diabetes, improper metabolism (fat metabolism), iCAT Therapy is able to achieve unique stabilization of diabetes complications, and in many cases, a reversal of the secondary complications of both Type 1 and Type 2 diabetes has been clinically documented. No other technology or protocol has ever demonstrated this type or level of success.
There are over 20.8 million children and adults in the United States, approximately 7% of the US population, who have diabetes. While an estimated 14.6 million have been diagnosed with diabetes, roughly 6.2 million people (or nearly one-third) are unaware that they have the disease.
In 2007, the total estimated cost of diabetes in the United States was $174 billion in terms of direct medical expenditures and lost productivity. Diabetes is more than a major health crisis - it’s a legitimate national threat to America’s economy. Jimmy McDougald, CEO, further stated, “With the only FDA approved device delivering this treatment, we will expect to sign agreements to start the establishment of iCAT Treatment Centers immediately.”
VitalCare Diabetes Treatment Centers, Inc.
BREAKTHROUGH MEDICAL TECHNOLOGY
VitalCare Diabetes Treatment Centers are leading the way to a healthier life for diabetics—
Understanding diabetes and the role of insulin
Diabetes is a common condition in which the amount of glucose (sugar) in the blood is too high because the body is unable to use it properly. This is because the body´s method of converting glucose into energy as the “primary fuel” for cellular metabolism is not working as it should. In fact, the cells compensate by switching to “fat metabolism” as the primary cellular fuel, since they can’t use glucose due to insulin insufficiency or the liver's desensitization to insulin. Diabetes can lead to serious complications, such as heart disease, strokes, amputations, eye and kidney damage, and premature death. The hormone, insulin, carefully controls the amount of glucose in the blood. Insulin is produced by the pancreas and triggers enzymatic processes within the liver which allows glucose to enter the cells where it is used as the “primary fuel” source throughout the body.
Many people with Type 1 and Type 2 diabetes are dependent on insulin injections and are in jeopardy of persistent fluctuations of their blood sugar. Our micro-pulsed insulin treatment has been developed, tested and shown to be extremely effective. It is without any documented side effects or complications with over 100, 000 treatments given to date. This proprietary treatment protocol is precise and only requires one insulin treatment every 7-10 days. VitalCare Technology is working together with its strategic partners to turn this "Medical Miracle" into a diabetic, complication free…"Reality".
VitalCare's Medically accomplished team is moving this patented and FDA approved technology into the commercial market working with Certified Licensed Healthcare Providers who are delivering Intercellular Activation Therapy or “iCAT Therapy” in licensed “VitalCare Diabetes Treatment Centers”. The therapy uses a specially designed micro-dose pulsatile insulin pump that delivers micro-doses of insulin, identical to the way a normal pancreas secretes insulin into the blood stream delivering insulin to the liver during and after a meal, while “real-time” measurements of the patient’s blood sugar level and metabolic rate, using end-tidal CO2 measurements are obtained from the patient using a metabolic cart. This data is inputted into the computer adjusting the insulin dosage. The metabolic cart uses state-of-the-art technology to measure exhaled CO2 thru a small mouth piece. The result of “iCAT” treatment is the “reactivation” of the patient’s metabolism as seen with normalization of liver enzyme function which returns the body cells back to utilizing glucose, to optimize cellular metabolism. The iCAT Treatment leads to the stabilization and in many cases a reversal of secondary complications seen in Type 2 diabetes. Stabilization of Type 1 diabetes is seen, as well. No other technology or protocol has demonstrated this same level of success in clinical trials as iCAT Therapy.
VitalCare Diabetes Treatment Centers, Inc.
Highlights
VitalCare Technology key Issues
→ Demand for Insulin Delivery technologies that work is rising
→ Effectiveness of traditional insulin treatment showing decline with increasing Diabetic population
→ Type II diabetes therapy market is expected to exceed US $15.3 Billion by 2013
→ Oral dosing is currently under clinical trials with Insulin inhalers reaching the market in 2007
→ VitalCare Technology Enterprises’ Clinical, Medical, Scientific and Executive leaders are poised to create a new standard of care for the treatment of both Type I and Type II diabetes.
→ VitalCare signs strategic partnership with CAT Clinics, LLC, BIONICA International, Inc, & MedEdCo, LLC to market, sell, license and open Corporately owned CAT Clinics.
Press - VitalCare In The News
→ VitalCare Technology Enterprises is established for development of Intercellular Activation Therapy Diabetes Centers, affiliated with CAT Clinics, LLC, BIONICA International and MedEdCo Corporation.
→ “Stock Exchange” Agreements signed between VitalCare Technology, CAT Clinics, LLC, and MedEdCo Corporation, providing a co-ownership relationship between the three companies for the purpose of promotion and expansion of the iCAT Diabetes Center business opportunity Licensing Agreement Signed between VitalCare Technology and CAT Clinics, LLC and BIONICA International.
→ Management Service Agreement signed between VitalCare Technology and MedEdCo Corporation for ongoing clinical support, professional education and credentialing, and quality assurance services.
→ Setup and implement the Company Website at www.vitalcaretechnology.com Internet Link established between VitalCare Technology’s website at www.vitalcaretechnology.com and www.diabetes.net (Mr. Gregory Gilbert’s website) used to promote Intercellular Activation Therapy.
What Patients Are Saying:
→ In addition to published research articles in peer reviewed journals featuring iCAT therapy’s clinical success the Company will use its patient testimonials concerning the life-changing benefits they received from iCAT therapy as in the following documented patient testimonials:
→ “My neuropathy didn’t allow me to sleep at night. I was in constant pain from the knees down. My husband couldn’t sleep and nothing helped. After several weeks of Cellular Activation Therapy, I noticed changes. Now I take no pain medication at all and have no twinges.” (54, white, woman 28 years Type 1 on iCAT therapy for 8 years)
→ “ I am now independent and can go anywhere. I had severe cardiac myopathy. Since I have been on the program, I have lowered my insulin from 150 units per day to 24 units daily. It worked after 3 weeks. I have more energy; before, I slept all the time. I now have a very active life.” (53-year-old woman on a heart transplant list for 3 years; on iCAT therapy for 5 years.)
→ The youngest person ever to be treated with iCAT therapy to date started treatments at age 5. Today that little girls of 5 has attained the age of 32 and has become a mother for the third time. Her pregnancies were without any hypoglycemic events or hypertension, throughout each trimester, as she continued on iCAT therapy utilizing the in-home therapy protocol. As the first of the homecare test patients, she delivered healthy normal babies at full term without one side effect or complication and to date has never had any complications or side effects to iCAT therapy. Her picture can be seen on the “portal” website at: www.diabetes.net.
VitalCare Diabetes Treatment Centers, Inc. is a Bio-tech company that is commercializing a cutting edge FDA approved technology for treating metabolic disorders specifically targeting Type 1 and Type 2 Diabetes and Secondary Complications of Type 2 Diabetes. The Treatment is known as Intercellular Activation Therapy “iCAT” and uses an FDA approved, US and European patented micro-dose intravenous insulin pump combined with proprietary algorithms and peer reviewed clinical protocols.
Business
Approximately 100, 000 treatments spanning over the past 25+ years have been administered. proving the effectiveness of iCAT therapy with not one negative side effect or medical complication reported. There are a number of peer reviewed published articles by top medical researchers in the field of Diabetes, Wound Care and Endocrinology who've determined that iCAT Therapy is by far the most successful adjunct to traditional treatment for Secondary Complications of Type 2 Diabetes and treatment for Type 1 and Type 2 Diabetes.
VitalCare entered into an exclusive Licensing Agreement with the manufacturer of the patented and FDA approved micro-dose intravenous insulin pump and the exclusive developer of the proprietary algorithms and clinical protocols, who provides ongoing clinical oversight, medical training and quality control services to all certified VitalCare Diabetes Treatment Centers and affiliates. These exclusive licenses for North America include the USA, Canada and Mexico with further rights to expand internationally with some exclusions.
VitalCare will seek to open company owned VitalCare Diabetes Treatment Centers, identify and license the technology to healthcare specialists who meet stringent criteria for “Certification”, and license the iCAT Therapy to Insurance Plans and HMO’s under a Disease Management program. iCAT Therapy will initially be introduced to the consumer market as a rescue treatment for “Brittle Diabetic” patients suffering from secondary complications of Type 2 Diabetes, to include; difficult to heal wounds, high blood pressure, heart disease, visual impairment and kidney disease, using the patented and FDA approved micro-dose intravenous insulin pump device.
Currently, there are approximately 30 licensed iCAT clinics operating in North America, including Florida, Arizona, Utah, California, Texas and Nevada. VitalCare has an ownership joint-venture interest in two wound care centers in Indiana and has acquired joint ownership in the iCAT clinic located in Scottsdale, AZ. VitalCare is currently in negotiations for acquisitions with an iCAT clinic in Sacramento, CA and one in Draper, UT. VitalCare anticipates having clinics opened, either Company owned, joint venture or sub-licensed affiliates, in all fifty states by year end 2010.
Medical Devices
iCAT is delivered exclusively with the FDA approved, US and European patented micro-dose intravenous insulin pump device sold via an exclusive purchasing agreement through VitalCare. In addition to licensing and distribution of the insulin pumps, VitalCare will also market and distribute metabolic carts used to measure the patient’s Respiratory Quotient (“RQ”). In the future, VitalCare plans on licensing and marketing the proprietary pre-filled insulin cartridges that will operate only with VitalCare’s insulin pump technology.
iCAT Therapy has been independently proven to be safe and effective for Type 1 and Type 2 Diabetes and most secondary medical complications of Type 2 Diabetes with additional Medical Patents issued for; cardiovascular disease, diabetic wounds, retinopathy, secondary hypertension and kidney disease. In addition, iCAT Therapy has been found to improve all the general maladies of diabetes including lack of well-being, low energy, improving sleep, and there is anecdotal data on improvement in erectile dysfunction. iCAT Therapy has been proven safe and effective on the most difficult and critically ill patients who have failed all conventional therapies commonly referred to as “Brittle Diabetics”. Both patients and their physicians see positive results within a few treatment sessions. There is currently no other therapy known to have this high degree of clinical outcomes at or exceeding iCAT Therapy, with a documented 93%+ clinical outcome for patients between the ages of 5 years to 90+ years of age.
Mon, 21 Apr 2008 18:02:09 GMT
NEW YORK, NY--(MARKET WIRE)--Apr 21, 2008 -- Greenstone Holdings, Inc. (Other OTC:GSHN.PK - News) announced today that the Company appointed ECO Solutions Inc. a distributor for the GreenShield(TM) product line. Greenstone will supply Greenstone's protective chemical product, GreenShield(TM) to ECO Solutions on a non-exclusive basis for distribution to dealers and large end-users. ECO Solutions Inc. is an affiliate of ECORail Products Inc., the company who has an exclusive agreement for GreenShield process to be used on railroad wood products such as crossties, bridge members and railcar flooring and decking. ECO Solution's territory covers the states of Illinois, Indiana, Iowa, Kentucky, Michigan, Missouri, New York, Ohio, Pennsylvania, Virginia and Wisconsin.
ECO Solutions President & CEO B. Allen Brown stated, "We are extremely excited about the GreenShield product line and look forward to introducing it into the territories assigned by Greenstone. We have already experienced a high level of interest from the potential users we have already contacted."
Thu, 17 Apr 2008 19:55:26 GMT
NEW YORK, NY--(MARKET WIRE)--Apr 17, 2008 -- Greenstone Holdings, Inc. (Other OTC:GSHN.PK - News) announced today that the Company's flagship product, GreenShield™, was listed in one of the new product announcements in this month's Building Products Magazine. "Greenstone's GreenShield is formulated to protect building materials such as lumber, plywood, and drywall from water, moisture and fire. The thin, clear liquid reportedly penetrates and encapsulates the material at the molecular level. Totally organic, it quickly crystallizes without changing the material's color and resists UV rays, " said the article.
Wed, 16 Apr 2008 20:40:44 GMT
Greenstone Holdings, Inc. (PINKSHEETS: GSHN) announced today that the Company has introduced a new product, Fire-Pruf(TM) a special chemical to treat wood and make it completely fire-proof. Fire-Pruf(TM) has been invented by Mr. Toshio Ito of Nippon Funen Mokuzai(NFM) in Japan. NFM is also the manufacturer of Green-Dri(TM) Biological Dry Kiln. Fire-Pruf treated wood has recently been officially accepted by the Japanese Imperial Household Agency, a management agency overseeing the properties of Japanese Imperial families, many of which are wooden structures. The first delivery of Fire-Pruf treated cypress material was just made in late March.
"We are very excited about the introduction of Fire-Pruf especially for home owners in California, " said Sal Miwa, CEO of Greenstone.
Wed, 09 Apr 2008 01:28:38 GMT
Reported 2007 Revenues up 29% over 2006
HOLLYWOOD, Fla.--(BUSINESS WIRE)--Pricester.com, Inc. (OTCBB:PRCC - News), an Internet marketing and technology company, is continuing to grow. The company is reporting a 29% increase in annual revenues in its 2007 annual financial 10-K filing.
Pricester has shown a steady pattern of revenue growth over the last two years, supporting the organization’s planning and forecasting. Pricester has continued to penetrate the small business website market, as well as introducing exciting new online products, such as the rapidly growing Copia World (www.copiaworld.com), an international shopping portal featuring thousands of stores and businesses from 25 countries in thirteen consumer-friendly categories.
“Pricester has made important advances in fine-tuning basic services and web products, as well as identifying tremendous new opportunities for revenues. We also are continuing to investigate meaningful possibilities for mergers and acquisitions to promote value for our shareholders, ” said Ed Dillon, President & CEO. “Our reputation in the industry has expanded and our development of new products will spearhead our growth through 2008 and beyond as we continually narrow the margin to profitability, ” Dillon added.
PRICESTER ABOUT US
Pricester.Com is an e-commerce company currently operating a website that enables any business to establish a fully functional online retail presence. The company's website, http://www.Pricester.com, is an Internet marketplace which allows vendors to host their website with product and service listings and allows consumers to search for those same
Tue, 08 Apr 2008 14:22:04 GMT
NEW YORK, NY--(MARKET WIRE)--Apr 7, 2008 -- Greenstone Holdings, Inc. (Other OTC:GSHN.PK - News) announced today that the Company has introduced a new product MagneLine® StairSaf-T(TM) which is an innovative method to utilize specially designed Polymer Cement Mortar to protect metal stairs such as fire escape and ladders on high-rise buildings and pedestrian crossing bridges, from rust, corrosion, and also to add traction making it harder to slip under slippery conditions.
"There are thousands of fire escape stairs and pedestrian bridges in our major cities which are not protected from the weather and StairSaf-T(TM) will make them last longer and be safer for the travelers, " said Sal Miwa, CEO of Greenstone.
MagneLine is distributed exclusively in the United States by Greenstone for Magne Corporation in Fukuoka, Japan. See an example at http://www.egreenstone.com/documents/StairSaf-Tapplicationexample.pdf.
Inside Wall Street Report is a marketing firm that specializes in assisting companies that are currently in the small cap and micro cap stock market in getting the attention they deserve. Inside Wall Street Report Alerts eMarketing solutions are focused on helping financial service providers capture, cultivate and convert online sales stock leads - those prospects who are at your website, motivated, interested and in-market for your products or services.